C3 and COVID-19: The use of the C3 inhibitor AMY-101 in one patient withCOVID-19, who recovered (16), and the C5 activationinhibitor, eculizumab, as adjunctive treatment in four patients, who recovered (17), provide clinical evidence that complement may play apathogenic role in COVID-19.